.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC08_Decitabine.Decitabine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC08_Decitabine.Decitabine| name: | Decitabine |
| ATC code: | L01BC08 | route: | intravenous |
| n-compartments | 2 |
Decitabine is a DNA methyltransferase inhibitor used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is a cytidine analog that is incorporated into DNA, resulting in hypomethylation and activation of silenced genes. Decitabine is approved for medical use in various countries, including the US and EU, for hematological malignancies.
Pharmacokinetic parameters reported for adult patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following intravenous administration.
DiNardo, CD, et al., & Pollyea, DA (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology 19(2) 216–228. DOI:10.1016/S1470-2045(18)30010-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/29339097
Di Costanzo, A, et al., & Fiorentino, F (2025). Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy. ClinicoEconomics and outcomes research : CEOR 17 171–187. DOI:10.2147/CEOR.S495401 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40098920